Potential conflict of interest: Nothing to report.
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C
Article first published online: 6 MAY 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 2, pages 521–530, August 2014
How to Cite
Kazankov, K., Barrera, F., Møller, H. J., Bibby, B. M., Vilstrup, H., George, J. and Grønbæk, H. (2014), Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 60: 521–530. doi: 10.1002/hep.27129
Supported by the NOVO Nordisk Foundation, the Danish Strategic Research Council (10-092797), and grants from the National Health and Medical Research Council of Australia (632630, 1049857, 1053206) and the Robert W. Storr Bequest to the Sydney Medical Foundation of the University of Sydney.
- Issue published online: 22 JUL 2014
- Article first published online: 6 MAY 2014
- Accepted manuscript online: 13 MAR 2014 04:45AM EST
- Manuscript Accepted: 11 MAR 2014
- Manuscript Received: 14 MAY 2013
- The NOVO Nordisk Foundation
- The Danish Strategic Research Council . Grant Number: 10-092797
- The National Health and Medical Research Council of Australia . Grant Numbers: 632630 , 1049857 , 1053206
- The Robert W. Storr Bequest to the Sydney Medical Foundation of the University of Sydney
Additional Supporting Information may be found in the online version of this article at the publisher's website.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.